Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia

Michael E. O'Dwyer, Brian Druker

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The bcr-abl fusion protein is present in the vast majority of cases of chronic myelogenous leukemia, and the deregulated tyrosine kinase activity of this protein is essential for leukemic transformation. Thus, bcr-abl is an ideal target for pharmacologic inhibition. In preclinical studies, STI571 (formerly CGP57148B), an abl-specific, tyrosine kinase inhibitor, selectively killed bcr-abl-expressing cells both in vitro and in vivo. In early clinical trials of STI571, encouraging results have been obtained, and there is already a suggestion that STI571 may soon need to be incorporated into treatment algorithms for chronic myelogenous leukemia.

Original languageEnglish (US)
Pages (from-to)594-597
Number of pages4
JournalCurrent Opinion in Oncology
Volume12
Issue number6
DOIs
StatePublished - 2000

Fingerprint

bcr-abl Fusion Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Clinical Trials
Imatinib Mesylate

ASJC Scopus subject areas

  • Cancer Research

Cite this

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia. / O'Dwyer, Michael E.; Druker, Brian.

In: Current Opinion in Oncology, Vol. 12, No. 6, 2000, p. 594-597.

Research output: Contribution to journalArticle

@article{5e3038ebd7dc416290b3fbd5f8544d4e,
title = "Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia",
abstract = "The bcr-abl fusion protein is present in the vast majority of cases of chronic myelogenous leukemia, and the deregulated tyrosine kinase activity of this protein is essential for leukemic transformation. Thus, bcr-abl is an ideal target for pharmacologic inhibition. In preclinical studies, STI571 (formerly CGP57148B), an abl-specific, tyrosine kinase inhibitor, selectively killed bcr-abl-expressing cells both in vitro and in vivo. In early clinical trials of STI571, encouraging results have been obtained, and there is already a suggestion that STI571 may soon need to be incorporated into treatment algorithms for chronic myelogenous leukemia.",
author = "O'Dwyer, {Michael E.} and Brian Druker",
year = "2000",
doi = "10.1097/00001622-200011000-00013",
language = "English (US)",
volume = "12",
pages = "594--597",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia

AU - O'Dwyer, Michael E.

AU - Druker, Brian

PY - 2000

Y1 - 2000

N2 - The bcr-abl fusion protein is present in the vast majority of cases of chronic myelogenous leukemia, and the deregulated tyrosine kinase activity of this protein is essential for leukemic transformation. Thus, bcr-abl is an ideal target for pharmacologic inhibition. In preclinical studies, STI571 (formerly CGP57148B), an abl-specific, tyrosine kinase inhibitor, selectively killed bcr-abl-expressing cells both in vitro and in vivo. In early clinical trials of STI571, encouraging results have been obtained, and there is already a suggestion that STI571 may soon need to be incorporated into treatment algorithms for chronic myelogenous leukemia.

AB - The bcr-abl fusion protein is present in the vast majority of cases of chronic myelogenous leukemia, and the deregulated tyrosine kinase activity of this protein is essential for leukemic transformation. Thus, bcr-abl is an ideal target for pharmacologic inhibition. In preclinical studies, STI571 (formerly CGP57148B), an abl-specific, tyrosine kinase inhibitor, selectively killed bcr-abl-expressing cells both in vitro and in vivo. In early clinical trials of STI571, encouraging results have been obtained, and there is already a suggestion that STI571 may soon need to be incorporated into treatment algorithms for chronic myelogenous leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0034509139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034509139&partnerID=8YFLogxK

U2 - 10.1097/00001622-200011000-00013

DO - 10.1097/00001622-200011000-00013

M3 - Article

C2 - 11085460

AN - SCOPUS:0034509139

VL - 12

SP - 594

EP - 597

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -